Marco Meglio
@marcomeglio1
Followers
672
Following
19K
Media
127
Statuses
4K
Editor, @Neurology_Live 🧠| Hofstra Alum | Views are my own | 📧[email protected] | bagel and basketball enthusiast
Cranbury, NJ
Joined August 2011
We are onsite at #NSGC25 (@GeneticCouns) on behalf of CGTLive and our sister site @neurology_live! 🧠 View NeurologyLive's coverage here: https://t.co/3zVCTavaD2
0
3
2
Repetitive negative thinking is associated with cognitive decline. Stay positive.
371
6K
36K
How can we incorporate #AI to enhance #neurology education and clinical practice? Drs. Elisabeth Marsh, Raymond Price, and Rafael Llinas will be tackling this question in our upcoming #AUPN2025 Annual Meeting in Conjunction with the #ANA2025 Annual Meeting. Dr. Marsh joined
0
5
11
@marcomeglio1 Thank you for reporting on research released at #AAIC25 that shows a healthy lifestyle program targeting multiple risk factors can protect the cognitive function of at-risk older adults.
neurologylive.com
New research revealed that structured lifestyle programs could significantly enhance cognitive function in older adults at risk of decline, outperforming self-guided interventions.
1
2
2
We're looking forward to our #AUPN2025 session on using #simulations to evaluate non-medical knowledge competencies like teaching, professionalism, and communication skills! Session Moderator Dr. @NuriJacoby spoke with @marcomeglio1 from @NeurologyLive to give a short preview of
0
3
5
This was really fun to put together. For my neurology audience who specializes in sleep disorders, definitely a lot of great clinical nuggets you’re going to watch to check out!!
We've launched a new series with the @AASMorg! 🙌 🥳 In this Special Report, sleep expert Eric Olson, MD, and president-elect Anita Shelgikar, MD, break down six late-breaking presentations from the 2025 SLEEP Meeting. Episode 1, which focuses on the phase 4 XYLO study of
0
0
2
🧠 ICYMI: Dravet ≠ LGS. Dr. Joseph Sullivan, MD, breaks down how the two syndromes differ in seizure type, onset, genetic roots, and treatment strategies. This 10-minute listen can sharpen your diagnostic lens. 🎧 https://t.co/juWMtO7NWS
0
1
1
New 5-year findings from the National RLS Opioid Registry presented at #SLEEP2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome (#RLS)🧠 Learn more: https://t.co/I7MTGH5zXC
0
3
3
A must-attend session on refractory #status! #EEG #epilepsy @IlaeWeb @yesILAE @WashUNeurology
https://t.co/4vwtNpPsSf
1
18
56
💡Great insights from Dr. Seif Elbualy on the expanding role of non-surgical interventional pain mgmt including percutaneous procedures and devices. via @neurology_live
neurologylive.com
Seif Elbualy, MD, discusses his role at the Brain and Spine Symposium and shares insights on the future of interventional pain management, evolving techniques, and pharmaceutical innovation.
1
2
2
#DownSyndrome and #Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress https://t.co/jL7ZTpz6Ih by @marcomeglio1 @neurology_live
#science #neuroscience
1
7
12
Happy to share our review article about acute stroke therapeutics! https://t.co/tB4sGAAQ8e
0
4
10
In the final video of our Elevating Women in #Neurology series with @neurology_live, Drs. Marie Eugene, Vanessa Hinson, & @CarlayneJackson discussed key areas of women-focused neurology research, from inclusion in clinical trials to workforce challenges. https://t.co/tBovWTTQFm
1
2
4
#BREAKING: Last night, the @US_FDA approved Satsuma's dihydroergotamine nasal powder agent STS101, marketed as Atzumi, as a new treatment for patients with acute #migraine with or without aura. https://t.co/RnMOhJsL9h
neurologylive.com
Satsuma’s STS101 nasal powder becomes the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults.
0
2
3
#BREAKING: The @US_FDA has approved @JNJNews's nipocalimab, marketed as Imaavy, for the treatment of patients aged 12+ with myasthenia gravis for both anti-AChR and anti-MuSK forms🧠 More on the decision📲 https://t.co/FUE47UvSVf
neurologylive.com
Administered intravenously in a single-dose vial, nipocalimab becomes the second FDA-approved therapy for common forms of generalized myasthenia gravis, and the first for younger patients living with...
0
3
4
AUPN partnered with @neurology_live on a video series exploring the perspectives of women in #neurology. In this video, Dr. Marie Eugene, Dr. Vanessa Hinson, & Dr. @CarlayneJackson shared their advice for early-career women in neurology. https://t.co/uD3nN66BC1
@marcomeglio1
0
3
4
Women in #neurology face unique challenges, and Vanessa Hinson, MD, PhD (@MUSChealth), @CarlayneJackson, MD, FAAN (@AANmember), and Marie Eugene, DO (@uconnhealth) spoke with @marcomeglio1 from @neurology_live about strategies to overcome underrepresentation in leadership roles,
0
2
7
We were excited to partner with @neurologylive on this excellent series of videos! In our 2nd episode, Vanessa Hinson, MD, PhD (@MUSChealth), @CarlayneJackson, MD, FAAN (@AANmember), Marie Eugene, DO (@uconnhealth), and @marcomeglio1 discuss institutional policy changes that can
0
1
5
#BREAKING: The @US_FDA approved a new pre-filled syringe administration route for efgartigimod a marketed medication for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. @argenxglobal
https://t.co/cHLJmXcrp2
neurologylive.com
The prefilled syringe is approved for a 20- to 30-second subcutaneous injection, and patients can self-inject following proper instruction in the subcutaneous injection technique.
0
3
2
During #ADPD2025, Mary Hamby, PhD sat down with @marcomeglio1 from @neurology_live to discuss #zervimesine’s potential impact in #alzheimers treatment. Watch their full interview here: https://t.co/O3vI28yLch
#Dementia #DementiaWithLewyBodies #BiotechInnovation #ClinicalResearch
20
4
6